Eikon Therapeutics, Inc. EIKN
IPO
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 3.72% | -2.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.94% | 5.27% | |||
| Operating Income | -6.94% | -5.27% | |||
| Income Before Tax | -6.57% | -4.15% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.57% | -4.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.57% | -4.15% | |||
| EBIT | -6.94% | -5.27% | |||
| EBITDA | -7.48% | -5.87% | |||
| EPS Basic | 33.67% | 90.67% | |||
| Normalized Basic EPS | 33.67% | 90.64% | |||
| EPS Diluted | 33.67% | 90.67% | |||
| Normalized Diluted EPS | 33.67% | 90.64% | |||
| Average Basic Shares Outstanding | 60.66% | 1,015.95% | |||
| Average Diluted Shares Outstanding | 60.66% | 1,015.95% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||